|
|
| APC Payment Insider |
| April 2008 |
| Digest the new mandatory reporting requirements for ESA administration as of April 7 |
| In January, CMS published three transmittals that present sizeable operational challenges when billing for erythropoietin stimulating agents (ESA)-drugs such as EPO, DPO, Epogen, Procrit, and Aranesp. The transmittals include:
Transmittal 1412, Change Request 5699
Transmittal 1413, Change Request 5818
Transmittal 80, Change Request 5818
Although facilities that provide end-stage renal disease (ESRD) treatments are already familiar with these guidelines, other hospitals may find that the coverage and billing requirements are unfamiliar and difficult to implement. |
| APC Payment Insider subscribers, please sign on for access |
|
